Alector, Inc.

NASDAQ:ALEC

Biotechnology

Healthcare
$2.57 +5.13%

+$0.08 today

Market cap
$382.61M
Beta
0.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.13
52W Low $1.09High $3.40

Volume 2.13M

Average 0.65M

ALEC Purchases of Investments

Cash used to buy marketable securities and other investments.

Alector, Inc.NASDAQ: ALEC

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments declines year over year

Q1 FY2026 purchases of investments of $51.81M (cash outflow) fell 7.1% year over year, ahead of the -18.1% change in trailing-twelve-month purchases of investments. Sequentially, it fell 36.1% from the prior quarter. Over 3 fiscal years it compounded at -21.3% a year.

Context

  • Purchases of investments amounted to 1291.9% of revenue in FY2025, up 826.7 pp from a year earlier.
  • Purchases of investments grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -7.1% holds above the trailing-twelve-month pace of -18.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$51.81M-36.1% QoQ
Last fiscal yearDec 2025
-$271.88M-41.9% YoY
LTMMar 2026
-$267.89M-18.1% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.1%——
1 year-41.9%——
3-year CAGR-21.3%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(271.88M) USD
Year-over-year change
+41.9%

Purchases of Investments vs competitors

How ALEC compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -18.1% is the 4th highest of 8, against a peer median of -29.6%.
  • Purchases of investments amounts to 1454.6% of revenue for ALEC, versus a peer median of 1387.3%.
ALEC Competitors
Purchases of Investments for ALEC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$330.16M USD+33015900.0%-24.2%—
NKTXNkarta, Inc.LTM Mar 2026$272.26M USD-29.6%-14.8%—
ALECAlector, Inc.LTM Mar 2026$267.89M USD-18.1%-21.3%1454.6%
FATEFate Therapeutics, Inc.LTM Mar 2026$175.25M USD-37.4%-21.6%2774.7%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$136.21M USD+21.1%+23.6%—
PEPGPepGen Inc.LTM Mar 2026$115.7M USD-5.7%——
MOLNMolecular Partners AGLTM Mar 2026CHF 63.3M CHF-67.9%-39.5%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$43.83M USD-72.7%-2.9%—
IRDOpus Genetics, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding ALEC) —-29.6%-18.2%1387.3%

Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(36.33M)(133.31M)(130.39M)(119.05M)(142.93M)
Depreciation & Amortization8.32M8.47M8.85M8.84M(861K)
Deferred Income Tax00000
Stock-Based Compensation40.79M46.15M42.8M39.46M26.66M
Change in Working Capital283.68M59.53M(90.15M)(146.99M)(74.06M)
Accounts Receivables(7.39M)4.8M2.59M00
Inventory00000
Accounts Payables1.92M(572K)(377K)(1.44M)(524K)
Other Working Capital289.16M55.29M(92.36M)(145.55M)(73.53M)
Other Non-Cash Items2.1M(1.16M)(15.27M)(12.17M)7.16M
Operating Cash Flow298.55M(20.33M)(184.16M)(229.91M)(184.03M)
Capital Expenditures(3.25M)(4.12M)(2.38M)(1.26M)(41K)
Acquisitions (Net)00000
Purchases of Investments(343.4M)(556.9M)(551.73M)(467.74M)(271.88M)
Sales of Investments296.99M402M656.03M576.13M468.52M
Other Investing Activities00000
Investing Cash Flow(49.66M)(159.01M)101.92M107.13M196.6M
Debt Repayment0009.39M0
Common Stock Issued04.51M2.55M71.11M20M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities30.3M001.04M217K
Financing Cash Flow30.3M4.51M2.55M81.54M20.22M
Effect of Forex Changes00000
Net Change in Cash279.18M(174.83M)(79.69M)(41.23M)32.78M
Free Cash Flow295.3M(24.45M)(186.54M)(231.16M)(184.07M)

Alector, Inc.

NASDAQ:ALEC

Intrinsic Alpha fair value

Locked

Current Price

$2.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.